Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Summary

The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).

Timeline

Start

2010-10

Primary completion

2014-06

Completion

2014-06

Outcome

Missed primary endpoint

paper Amrubicin did not significantly improve the primary endpoint of PFS compared with docetaxel. PMID 28426104 ↗

Publications

• Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M, Tanaka H, Saito H, Saka H, Takeda K, Nogami N, Masuda N, Harada T, Kitagawa H, Horio H, Yamanaka T, Fukuoka M, Yamamoto N, Nakagawa K. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2017 Feb 1;28(2):285-291. doi: 10.1093/annonc/mdw621.

Drugs

Indications